Rhythm Pharmaceuticals, Inc. (NasdaqGM: RYTM)
Health Care · Biotechnology · US
$90.26
-0.58% today · -9.9% 1Y
Rhythm Pharmaceuticals, Inc. (NasdaqGM: RYTM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.25B and employs 414 people.
Over the last twelve months the share price has lost 9.9%, trading between 74.50 and 122.20.
Tweenvest scores Rhythm Pharmaceuticals, Inc. across four factors: quality 38/100, value 79/100. Its strongest factor is value.
RYTM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.25B
- Revenue (TTM)
- $239.92M
- P/E
- —
- EPS
- -3.12
- Dividend yield
- —
- Beta (5Y)
- 2.01
- 52-week high
- $122.20
- 52-week low
- $74.50
- Avg volume (3M)
- —
- Shares outstanding
- 68.85M
- Employees
- 414
- Next earnings
- —
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
- ISIN
- US76243J1051
- Founded
- 2008
- Listed since
- Oct 9, 2017
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Grifols, S.A.BME: GRF | $6.62B | €10.02 | +1.42% |
| Immunovant, Inc.NasdaqGS: IMVT | $6.29B | $29.81 | -2.17% |
| GRAIL, Inc.NasdaqGS: GRAL | $6.28B | $136.62 | -2.82% |
| Kodiak Sciences Inc.NasdaqGM: KOD | $6.26B | $98.84 | -1.03% |
| Kiniksa Pharmaceuticals International, plcNasdaqGS: KNSA | $6.22B | $80.31 | +0.66% |
| Biocon LimitedNSEI: BIOCON | $5.88B | Rs349.40 | -5.75% |
| CG Oncology, Inc.NasdaqGS: CGON | $5.66B | $63.58 | -0.38% |
| Erasca, Inc.NasdaqGS: ERAS | $5.61B | $15.63 | -2.53% |
Figures last refreshed Oct 11, 2026.